• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO's pharmacovigilance database.

作者信息

Morice Pierre-Marie, Khalife-Hachem Sabine, Sassier Marion, Lelong-Boulouard Véronique, Danu Alina, Pasquier Florence, Renneville Aline, Dolladille Charles, Micol Jean-Baptiste

机构信息

Department of Pharmacology, Caen-Normandy University Hospital, Caen, France.

Normandie Univ, UNICAEN, INSERM U1086 'Interdisciplinary Research Unit for Cancers Prevention and Treatment' (ANTICIPE), Caen, France.

出版信息

Blood Cancer J. 2024 Oct 14;14(1):177. doi: 10.1038/s41408-024-01154-z.

DOI:10.1038/s41408-024-01154-z
PMID:39402057
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11473840/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0be7/11473840/653f66f57610/41408_2024_1154_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0be7/11473840/653f66f57610/41408_2024_1154_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0be7/11473840/653f66f57610/41408_2024_1154_Fig1_HTML.jpg

相似文献

1
Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO's pharmacovigilance database.来那度胺治疗多发性骨髓瘤患者时发生的急性淋巴细胞白血病：随机对照试验的安全性荟萃分析及结合世界卫生组织药物警戒数据库的回顾性研究
Blood Cancer J. 2024 Oct 14;14(1):177. doi: 10.1038/s41408-024-01154-z.
2
Thalidomide and lenalidomide: overview of the French pharmacovigilance database.沙利度胺和来那度胺：法国药物警戒数据库概述
Prescrire Int. 2012 Mar;21(125):72.
3
Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma.一名多发性骨髓瘤患者在来那度胺维持治疗期间发生急性淋巴细胞白血病。
Leuk Lymphoma. 2013 Dec;54(12):2753-5. doi: 10.3109/10428194.2013.786072.
4
B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review.老年男性患浆细胞骨髓瘤伴长期沙利度胺和来那度胺暴露后的 B 细胞急性淋巴细胞白血病：病例报告及文献复习。
BMC Cancer. 2019 Nov 27;19(1):1147. doi: 10.1186/s12885-019-6286-9.
5
Treatment-Associated Acute Lymphoblastic Leukemia Following Autologous Hematopoietic Stem Cell Transplant and Lenalidomide Maintenance in Patients With Multiple Myeloma.自体造血干细胞移植和来那度胺维持治疗多发性骨髓瘤后治疗相关性急性淋巴细胞白血病。
J Investig Med High Impact Case Rep. 2022 Jan-Dec;10:23247096221133204. doi: 10.1177/23247096221133204.
6
(Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.硼替佐米联合来那度胺/沙利度胺与硼替佐米或来那度胺/沙利度胺联合方案作为初治多发性骨髓瘤诱导治疗的疗效比较：一项随机对照试验的荟萃分析。
Ann Hematol. 2012 Nov;91(11):1779-84. doi: 10.1007/s00277-012-1520-4. Epub 2012 Jul 7.
7
Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs.接受免疫调节药物治疗的黑人患者皮肤色素沉着过度的发生率。
Blood. 2021 May 27;137(21):2987-2989. doi: 10.1182/blood.2021010853.
8
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.来那度胺联合地塞米松治疗复发或难治性多发性骨髓瘤患者，无论之前是否使用过沙利度胺，均比单独使用地塞米松更有效。
Blood. 2008 Dec 1;112(12):4445-51. doi: 10.1182/blood-2008-02-141614. Epub 2008 Sep 17.
9
Lenalidomide: second cancers.来那度胺：二次癌症
Prescrire Int. 2012 May;21(127):130.
10
Lenalidomide and secondary acute lymphoblastic leukemia: a case series.来那度胺与继发性急性淋巴细胞白血病：病例系列
Hematol Oncol. 2017 Mar;35(1):130-134. doi: 10.1002/hon.2248. Epub 2015 Jul 31.

引用本文的文献

1
Acute pro-B-cell lymphoblastic leukemia evolving from myelodysplastic neoplasm post cytotoxic therapy: a case report.细胞毒性治疗后由骨髓增生异常肿瘤演变而来的急性前体B细胞淋巴细胞白血病：一例报告
Haematologica. 2025 Aug 1;110(8):1894-1897. doi: 10.3324/haematol.2025.287357. Epub 2025 Apr 10.
2
Pharmacovigilance study of immunomodulatory drug-related adverse events using spontaneous reporting system databases.利用自发报告系统数据库进行免疫调节药物相关不良事件的药物警戒研究。
Int J Immunopathol Pharmacol. 2025 Jan-Dec;39:3946320251327618. doi: 10.1177/03946320251327618. Epub 2025 Apr 10.

本文引用的文献

1
Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis.伴有髓系突变的急性淋巴细胞白血病是一种与克隆性造血相关的高危疾病。
Blood Cancer Discov. 2024 May 1;5(3):164-179. doi: 10.1158/2643-3230.BCD-23-0106.
2
Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial.来那度胺维持治疗新诊断的适合和不适合移植的骨髓瘤患者；对骨髓瘤XI试验中4358例患者的第二原发性恶性肿瘤进行分析。
EClinicalMedicine. 2023 Jul 27;62:102099. doi: 10.1016/j.eclinm.2023.102099. eCollection 2023 Aug.
3
Therapy-related myelodysplastic syndromes in the genomics era.
基因组时代相关治疗的骨髓增生异常综合征。
Bull Cancer. 2023 Nov;110(11):1129-1140. doi: 10.1016/j.bulcan.2023.02.022. Epub 2023 Jun 28.
4
'Secondary' acute lymphoblastic/lymphocytic leukemia - done playing second fiddle?继发性急性淋巴细胞白血病/淋巴细胞性白血病——不再是配角？
Blood Rev. 2023 Jul;60:101070. doi: 10.1016/j.blre.2023.101070. Epub 2023 Mar 5.
5
Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic TP53-Mutant Clonal Hematopoiesis.成人低二倍体急性淋巴细胞白血病源自白血病前期 TP53 突变的克隆性造血。
Blood Cancer Discov. 2023 Mar 1;4(2):134-149. doi: 10.1158/2643-3230.BCD-22-0154.
6
Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma.来那度胺治疗多发性骨髓瘤后出现的 B-ALL 具有独特的克隆特征。
Blood Adv. 2023 Jan 24;7(2):236-245. doi: 10.1182/bloodadvances.2022007496.
7
Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.PARP抑制剂治疗相关的髓系肿瘤：真实世界经验
Clin Cancer Res. 2022 Dec 1;28(23):5211-5220. doi: 10.1158/1078-0432.CCR-22-1622.
8
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.世界卫生组织血液淋巴肿瘤分类第五版：髓系和组织细胞/树突状肿瘤。
Leukemia. 2022 Jul;36(7):1703-1719. doi: 10.1038/s41375-022-01613-1. Epub 2022 Jun 22.
9
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.来那度胺可促进 TP53 突变的治疗相关髓系肿瘤的发展。
Blood. 2022 Oct 20;140(16):1753-1763. doi: 10.1182/blood.2021014956.
10
Cancer therapy shapes the fitness landscape of clonal hematopoiesis.癌症治疗改变了克隆性造血的适应性景观。
Nat Genet. 2020 Nov;52(11):1219-1226. doi: 10.1038/s41588-020-00710-0. Epub 2020 Oct 26.